ESO Lymphoma Course

 

ESO Lymphoma Course
Avatar

The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment, TP53 Status, 2nd Line Setting and MRD

By ESO Lymphoma Course FEATURING Davide Rossi
By ESO Lymphoma Course FEATURING Davide Rossi
0 views
August 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Videos
18:40
ESO Lymphoma Course

Chemo-free Therapy for Follicular Lymphoma - Rituximab as Single Age…

Feat. E. Zucca
39:10
ESO Lymphoma Course

Hodgkin Lymphoma - Kairos vs. Chronos Principle & New Active Age…

Feat. P. Johnson
14:43
ESO Lymphoma Course

The Mutational Landscape of CLL: Diagnosis, Survival, and Watch and …

Feat. D. Rossi
19:04
ESO Lymphoma Course

The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment,…

Feat. D. Rossi
22:43
ESO Lymphoma Course

R-CHOP Therapy for 61 y/o Male with Stage IIIB bulky DLBCL & Avo…

Feat. A. Moccia
23:01
ESO Lymphoma Course

Treatment of 58 y/o Male with Stage IV B Marginal Zone lLymphoma : T…

Feat. A. Moccia
31:37
ESO Lymphoma Course

Efficacy and Safety of Anti-CD19 CAR T-cell Therapy in B-cell Lympho…

Feat. S. Neelapu
26:51
ESO Lymphoma Course

Management of Mantle Cell Lymphoma: Prognostic Factors, Younger vs. …

Feat. S. Rule
31:53
ESO Lymphoma Course

Update on Primary and Secondary CNS Lymphoma: Diagnosis, Treatment O…

Feat. T. Batchelor
18:27
ESO Lymphoma Course

Update on Waldenstrom's Macroglobulinemia: Somatic Mutation in …

Feat. B. Gerber
22:17
ESO Lymphoma Course

First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CH…

Feat. A. Davies
18:20
ESO Lymphoma Course

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezom…

Feat. A. Davies
09:10
ESO Lymphoma Course

Evolution of Cancer Therapies: Molecular Selection of Patients, Hist…

Feat. A. Stathis
09:22
ESO Lymphoma Course

Main Phases of Clinical Drug Development, New Trials Designs (Umbrel…

Feat. A. Stathis
07:54
ESO Lymphoma Course

Current and Future Drug Development in DLBCL: Review of Methodology,…

Feat. A. Stathis
21:39
ESO Lymphoma Course

Case of 58 y/o Male with IgM Multiple Myeloma and Amyloidosis: Disea…

Feat. B. Gerber
11:39
ESO Lymphoma Course

Treatment of 57 y/o Male with B-Lymphoblastic Lymphoma

Feat. B. Gerber
32:00
ESO Lymphoma Course

The AML Paradigm: From 3+7 for Everybody to Genetic-Driven Personali…

Feat. M. Fey
33:55
ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

Feat. A. Melnick
22:37
ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP,…

Feat. A. Melnick
16:32
ESO Lymphoma Course

Biology of T-cell Lymphoma: PTCL Molecular Characterisation & En…

Feat. L. de Leval
12:07
ESO Lymphoma Course

Biology of Anaplastic Large Cell Lymphomas (ALK+ and ALK-) & Bre…

Feat. L. de Leval
17:15
ESO Lymphoma Course

Biology of Extranodal NK/T-cell Lymphoma: Mutations and Pathways, EA…

Feat. L. de Leval
28:05
ESO Lymphoma Course

Biology of Hodgkin Lymphoma: IgV Gene Rearrangements, Factors Contri…

Feat. R. Küppers
22:48
ESO Lymphoma Course

Biology of Hodgkin Lymphoma: Relationship Between Hodgkin and Reed-S…

Feat. R. Küppers